- Fresenius Medical Care (NYSE:FMS) has restructured its operating model with changes to the management board effective Jan. 01, 2022.
- German-based healthcare services provider focused on renal care has established two new units operating globally: Care Delivery segment and Care Enablement segment.
- Led by William Valle, Fresenius Medical’s (FMS) current CEO for North America, the Care Delivery segment will combine the global healthcare services business.
- Managed by Katarzyna Mazur-Hofsäß, the company’s current CEO for Europe, Middle East, and Africa (EMEA) region, the Care Enablement segment will house healthcare products business under a MedTech unit.
- While Rice Powell remains CEO of Fresenius Medical (FMS), Harry de Wit, CEO for Asia-Pacific, Kent Wanzek, CEO for Global Manufacturing, Quality and Supply (GMQS), Olaf Schermeier, CEO for R&D will join the company’s executive committee from its management board.
- Recently, Fresenius Medical (FMS) announced a strategic distribution partnership with JMS Co., covering the Japanese market.